Eli Lilly Share Price – Current Range and Forecast
Eli Lilly and Company shares currently trade between $920 and $940 on the New York Stock Exchange, reflecting persistent volatility within the pharmaceutical sector. The stock has retreated from its all-time high of $972.53 reached on August 22, 2024, with recent trading sessions recording declines between 0.91% and 1.98%.
Market data reveals significant pricing discrepancies across platforms, with figures ranging from $639.43 to $935.58 depending on the timestamp and data provider. Investors monitoring LLY face a landscape of mixed analyst sentiment, recent earnings beats, and technical chart patterns suggesting divergent future targets.
This examination tracks the current valuation metrics, performance drivers, and forecast models influencing one of the market’s most actively traded healthcare equities.
What Is the Current Eli Lilly Share Price?
Real-time data positions Eli Lilly stock within a narrow band, though exact figures vary by source. TradingView lists a recent close at $922.64, down 0.91% in 24 hours, while TradingEconomics recorded $927.06 on April 6. YCharts data from April 2 showed $935.58, reflecting a 1.98% decline.
Key metrics define the current trading environment:
- Shares trade on the NYSE under ticker symbol LLY
- Recent session high reached $938.68 with a low of $919.82
- Market capitalization fluctuates between approximately $782 billion and $875 billion
- Price-to-earnings ratio sits at 40.76 to 41.42
- Trading volume of 1.82 million shares trails the three-month average of 3.28 million
- Beta of 0.64 suggests lower volatility relative to broader market indices
- Year-to-date performance shows declines of 8.36% in some metrics
| Ticker | LLY |
|---|---|
| Exchange | NYSE |
| Current Range | $920–$940 |
| 52-Week High | $1,133.95 |
| 52-Week Low | $623.78 |
| Market Cap | $875.67B (upper estimate) |
| P/E Ratio | 41.42 |
| Next Earnings | Q1 2026 (forecast) |
| All-Time High | $972.53 (Aug 22, 2024) |
| Average Volume | 3.28M |
How Has Eli Lilly Stock Performed Recently?
The equity has navigated a turbulent 52-week range, spanning from a low of $623.78 to a high of $1,133.95. This breadth illustrates the stock’s sensitivity to drug pipeline news and broader healthcare sector rotations.
Historical Highs and Recent Lows
The all-time high of $972.53 established in August 2024 remains the benchmark for bullish sentiment. Since then, the stock has encountered pressure, hitting an 18-week low of $956.91 according to recent data from TradingEconomics. Four-week lows touched $1,000, while seven-week lows settled near $1,004.
Volatility and Trading Patterns
Current volatility measures 1.89%, with technical analysts identifying a downward channel characterized by resistance near $772–$780 and support around $720–$709. The stock’s beta of 0.64 theoretically indicates less dramatic swings than the overall market, though recent daily ranges suggest otherwise.
Price quotes vary significantly across platforms. Investing.com listed a price of $639.43 in after-hours trading, while official Lilly investor relations data showed ranges between $930.02 and $957.69. These variations likely stem from timestamp differences around early April 2026 rather than actual arbitrage opportunities.
Why Is Eli Lilly Share Price Changing?
Recent price action stems primarily from earnings performance and shifting analyst sentiment regarding the company’s growth trajectory.
Earnings Performance and Forecasts
The company has consistently exceeded earnings expectations. Fourth quarter 2025 results delivered $7.54 per share against a consensus of $7.16. Third quarter 2025 similarly beat projections with $7.02 versus $6.36 expected. However, the forecast for first quarter 2026 suggests $7.25, below the consensus of $3.34 in some models, creating uncertainty.
Analyst Rating Revisions
Institutional sentiment has cooled recently. Daiwa Securities downgraded the stock from Outperform to Neutral on August 18, 2025, establishing a $700 price target. Leerink Partners followed on August 7, 2025, reducing their rating from Outperform to Market Perform with a $715 target.
One data source indicates a dividend yield of 66.6%, a figure that requires independent verification. This percentage appears inconsistent with standard pharmaceutical payout ratios and may reflect a data processing error or special distribution not yet confirmed by official filings.
What Is the Eli Lilly Stock Forecast?
Forecasting models present conflicting trajectories, with technical patterns suggesting both significant upside potential and bearish reversals.
Price Targets and Technical Scenarios
Analysts have established a wide forecast range, with maximum targets reaching $1,190 and minimum targets dropping to $700. Technical charts reveal bullish flag patterns targeting $1,250 if the stock breaks above resistance at $972–$973. Conversely, bearish interpretations suggest potential declines toward $35–$17, though these projections appear highly speculative.
Options Market Indicators
Derivative markets show specific interest in October 31, 2025 expiration $850 call options, with analysis suggesting a 24% return on investment potential. This activity indicates institutional positioning for a recovery above current levels within the next several months.
Chart patterns currently offer contradictory signals. While bullish formations suggest targets exceeding $1,200, downward channel resistance and recent downgrades create headwinds. Price action near the $972 level will likely determine whether the intermediate trend breaks upward or continues consolidation.
Eli Lilly Key Fundamentals
Beyond daily price movements, the company’s valuation metrics reflect its status as a large-cap pharmaceutical leader. The price-to-sales ratio stands at 13.08, with price-to-book value reaching 31.50. These multiples position Lilly at a premium compared to traditional value plays in the sector.
Yearly performance shows gains between 7.38% and 16.26% over trailing twelve-month periods, with year-to-date figures of 15.17% in certain measurements. The disparity in performance metrics highlights the importance of verifying calculation methodologies across data providers.
When Are Eli Lilly’s Key Financial Dates?
Recent history and upcoming expectations shape trading schedules:
- – Stock reaches all-time high of $972.53
- – Options expiration for $850 calls showing high open interest
- – Q3 2025 earnings reported at $7.02 per share, beating $6.36 consensus
- – Q4 2025 earnings deliver $7.54 versus $7.16 expected
- – Q1 2026 earnings anticipated, with forecasts suggesting $7.25 EPS
What Do We Know for Certain About LLY Stock?
Separating verified data from speculation helps clarify the investment landscape.
Established Information
- Official NYSE listing under ticker LLY
- Q4 2025 earnings exceeded consensus estimates
- Recent trading sessions ranged between $919.82 and $938.68
- Market capitalization approximates $875 billion
- P/E ratio consistently reported between 40.76 and 41.42
Information That Remains Unclear
- Exact dividend yield (66.6% figure appears anomalous)
- Short-term price direction due to conflicting technical patterns
- Specific calendar date for Q1 2026 earnings announcement
- Whether bearish flag targets below $20 represent genuine risk or algorithmic artifacts
How Does Eli Lilly Fit Into the Broader Market?
As one of the largest pharmaceutical companies by market capitalization, Eli Lilly’s price action often reflects sector-wide sentiment regarding drug pricing, regulatory approvals, and obesity treatment demand. The company’s valuation premium suggests investors price in significant future revenue growth from its diabetes and weight management portfolios.
While unrelated to pharmaceutical markets, investors tracking diverse asset classes might also follow major international sporting events. For those interested in youth athletics history, the Under 17 World Cup – Winners List, History and Key Facts provides comprehensive tournament records.
What Are Market Experts Saying?
Recent analyst actions reflect growing caution despite strong earnings performance.
“Daiwa Securities adjusted their rating from Outperform to Neutral, citing valuation concerns with a revised price target of $700.”
— Analyst rating update, August 18, 2025
“Technical charts currently display a downward channel with resistance near $772–$780, though bullish breakout patterns targeting $1,250 emerge if $972–$973 resistance fails.”
— TradingView Technical Analysis
Key Takeaways on Eli Lilly Share Price
Eli Lilly trades within a volatile $920–$940 range, down from August 2024 peaks above $972, as investors weigh strong Q4 2025 earnings against recent analyst downgrades and technical uncertainty. With market capitalization near $875 billion and P/E ratios above 40, the stock commands a premium valuation requiring careful monitoring of Q1 2026 results and resistance levels near $973. For those planning travel to filming locations unrelated to financial markets, Game of Thrones Ireland – Filming Locations Tours Maps 2025 offers detailed tourism guidance.
Frequently Asked Questions
Is Eli Lilly stock a good buy?
Analyst ratings are currently mixed, with recent downgrades to Neutral and Market Perform suggesting caution despite strong earnings beats. Price targets range from $700 to $1,190.
What is Eli Lilly’s dividend yield?
The dividend yield remains uncertain. While one source lists 66.6%, this figure appears anomalous and requires verification against official SEC filings.
Why do different websites show different prices for LLY?
Timestamp variations around early April 2026 create discrepancies between platforms. Real-time data from official Lilly investor relations provides the most accurate delayed quotes.
What is the LLY ticker symbol?
Eli Lilly and Company trades on the New York Stock Exchange under the ticker symbol LLY.
How often does Eli Lilly report earnings?
The company follows a quarterly reporting schedule, with recent Q4 2025 results announced and Q1 2026 results expected in April 2026.
What is the 52-week range for Eli Lilly stock?
Shares have traded between $623.78 and $1,133.95 over the past 52 weeks, with an all-time high of $972.53 reached on August 22, 2024.
More related posts
2.4 Metres in Feet: 7 ft 10.5 in Conversion Guide
Hotels in Galway City Centre – Top Picks and Prices 2025
PSG vs Atlético Madrid Stats: H2H, 4-0 Score & Key Metrics
Castleknock Lawn Tennis Club: Membership, Menu & Reviews
VFS Ireland Visa Tracking – Status Guide and Timelines
How to Find My Phone Samsung: SmartThings Find Guide
Bundee Aki Dropped from Ireland Squad: Disciplinary Reasons
Oldest Person in the World: Verified Records & Current Holder
